Search

Your search keyword '"Yedilbayev, A."' showing total 9 results
Start Over "Yedilbayev, A." Journal clinical infectious diseases
9 results on '"Yedilbayev, A."'

1. Safety and effectiveness of three novel all-oral shortened regimens for rifampicin- or multidrug-resistant tuberculosis in Kazakhstan

Author

Rashitov, Makhmujan, primary, Franke, Molly, additional, Trevisi, Letizia, additional, Bekbolatova, Gulzhanat, additional, Shalimova, Julia, additional, Eshmetov, Gafurzhan, additional, Bektasov, Sagit, additional, LaHood, Allison, additional, Arlyapova, Nataliya, additional, Osso, Elna, additional, Yedilbayev, Askar, additional, Korotych, Oleksandr, additional, Ciobanu, Anisoara, additional, Skrahina, Alena, additional, Mitnick, Carole D, additional, Seung, Kwonjune, additional, Algozhin, Yerkebulan, additional, and Rich, Michael L, additional

Published
2024
Full Text
View/download PDF

2. Safety and Effectiveness of 3 Novel All-Oral Shortened Regimens for Rifampicin- or Multidrug-Resistant Tuberculosis in Kazakhstan.

Author

Rashitov, Makhmujan, Franke, Molly F, Trevisi, Letizia, Bekbolatova, Gulzhanat, Shalimova, Julia, Eshmetov, Gafurzhan, Bektasov, Sagit, LaHood, Allison, Arlyapova, Nataliya, Osso, Elna, Yedilbayev, Askar, Korotych, Oleksandr, Ciobanu, Anisoara, Skrahina, Alena, Mitnick, Carole D, Seung, Kwonjune J, Algozhin, Yerkebulan, and Rich, Michael L

Subjects
ANTIBIOTICS, HETEROCYCLIC compounds, PYRAZINAMIDE, COMBINATION drug therapy, PATIENT safety, RESEARCH funding, FLUOROQUINOLONES, ORAL drug administration, TREATMENT effectiveness, TREATMENT duration, DESCRIPTIVE statistics, ANTITUBERCULAR agents, QUINOLONE antibacterial agents, LONGITUDINAL method, LINEZOLID, CONFIDENCE intervals, RIFAMPIN
Abstract

Background In 2019, the World Health Organization called for operational research on all-oral shortened regimens for multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). We report safety and effectiveness of three 9-month all-oral regimens containing bedaquiline (Bdq), linezolid (Lzd), and levofloxacin (Lfx) and reinforced with cycloserine (Cs) and clofazimine (Cfz), delamanid (Dlm) and pyrazinamide (Z), or Dlm and Cfz. Methods We conducted a prospective cohort study of patients initiating treatment for pulmonary MDR/RR-TB under operational research conditions at public health facilities in Kazakhstan. Participants were screened monthly for adverse events. Participants with baseline resistance were excluded from the study and treated with a longer regimen. We analyzed clinically relevant adverse events of special interest in all participants and sputum culture conversion and end-of-treatment outcomes among individuals who were not excluded. Results Of 510 participants, 41% were women, the median age was 37 years (25th–75th percentile: 28–49), 18% had a body mass index <18.5 kg/m2, and 51% had cavitary disease. A total of 399 (78%) initiated Bdq-Lzd-Lfx-Cs-Cfz, 83 (16%) started Bdq-Lzd-Lfx-Dlm-Z, and 28 (5%) initiated Bdq-Lzd-Lfx-Dlm-Cfz. Fifty-eight individuals (11%) were excluded from the study, most commonly due to identification of baseline drug resistance (n = 52; 90%). Among the remaining 452 participants, treatment success frequencies were 92% (95% CI: 89–95%), 89% (95% CI: 80–94%), and 100% (95% CI: 86–100%) for regimens with Cs/Cfz, Dlm/Z, and Dlm/Cfz, respectively. Clinically relevant adverse events of special interest were uncommon. Conclusions All regimens demonstrated excellent safety and effectiveness, expanding the potential treatment options for patients, providers, and programs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Aggressive Regimens Reduce Risk of Recurrence After Successful Treatment of MDR-TB

Author

I Y Gelmanova, Nataliya A. Zemlyanaya, Molly F. Franke, Yevgeniy G. Andreev, Mercedes C. Becerra, Valentina I. Berezina, Sonya Shin, Askar Yedilbayev, Sidney Atwood, Faiz Ahmad Khan, Vera E. Pavlova, Salmaan Keshavjee, and Irina A. Unakova

Subjects
Adult, Male, Risk, Microbiology (medical), medicine.medical_specialty, Tuberculosis, Antitubercular Agents, Lower risk, Drug Administration Schedule, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Recurrence, Interquartile range, Internal medicine, Tuberculosis, Multidrug-Resistant, Secondary Prevention, Culture conversion, Humans, Medicine, 030212 general & internal medicine, Retrospective Studies, business.industry, Hazard ratio, Retrospective cohort study, medicine.disease, Confidence interval, Surgery, Regimen, Treatment Outcome, Infectious Diseases, 030228 respiratory system, Drug Therapy, Combination, Female, business, Follow-Up Studies
Abstract

Background We sought to determine whether treatment with a "long aggressive regimen" was associated with lower rates of relapse among patients successfully treated for pulmonary multidrug-resistant tuberculosis (MDR-TB) in Tomsk, Russia. Methods We conducted a retrospective cohort study of adult patients that initiated MDR-TB treatment with individualized regimens between September 2000 and November 2004, and were successfully treated. Patients were classified as having received "aggressive regimens" if their intensive phase consisted of at least 5 likely effective drugs (including a second-line injectable and a fluoroquinolone) used for at least 6 months post culture conversion, and their continuation phase included at least 4 likely effective drugs. Patients that were treated with aggressive regimens for a minimum duration of 18 months post culture conversion were classified as having received "long aggressive regimens." We used recurrence as a proxy for relapse because genotyping was not performed. After treatment, patients were classified as having disease recurrence if cultures grew MDR-TB or they re-initiated MDR-TB therapy. Data were analyzed using Cox proportional hazard regression. Results Of 408 successfully treated patients, 399 (97.5%) with at least 1 follow-up visit were included. Median duration of follow-up was 42.4 months (interquartile range: 20.5-59.5), and there were 27 recurrence episodes. In a multivariable complete case analysis (n = 371 [92.9%]) adjusting for potential confounders, long aggressive regimens were associated with a lower rate of recurrence (adjusted hazard ratio: 0.22, 95% confidence interval, .05-.92). Conclusions Long aggressive regimens for MDR-TB treatment are associated with lower risk of disease recurrence.

Published
2016

6. Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis

Author

Seung, Kwonjune J, primary, Khan, Palwasha, additional, Franke, Molly F, additional, Ahmed, Saman, additional, Aiylchiev, Stalbek, additional, Alam, Manzur, additional, Putri, Fauziah Asnely, additional, Bastard, Mathieu, additional, Docteur, Wisny, additional, Gottlieb, Gary, additional, Hewison, Catherine, additional, Islam, Shirajul, additional, Khachatryan, Naira, additional, Kotrikadze, Tinatin, additional, Khan, Uzma, additional, Kumsa, Andargachew, additional, Lecca, Leonid, additional, Tassew, Yoseph Melaku, additional, Melikyan, Nara, additional, Naing, Ye Yint, additional, Oyewusi, Lawrence, additional, Rich, Michael, additional, Wanjala, Stephen, additional, Yedilbayev, Askar, additional, Huerga, Helena, additional, and Mitnick, Carole D, additional

Published
2019
Full Text
View/download PDF

7. Aggressive Regimens Reduce Risk of Recurrence After Successful Treatment of MDR-TB

Author

Ahmad Khan, Faiz, primary, Gelmanova, Irina Y., additional, Franke, Molly F., additional, Atwood, Sidney, additional, Zemlyanaya, Nataliya A., additional, Unakova, Irina A., additional, Andreev, Yevgeniy G., additional, Berezina, Valentina I., additional, Pavlova, Vera E., additional, Shin, Sonya S., additional, Yedilbayev, Askar B., additional, Becerra, Mercedes C., additional, and Keshavjee, Salmaan, additional

Published
2016
Full Text
View/download PDF

8. Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis.

Author

Seung, Kwonjune J, Khan, Palwasha, Franke, Molly F, Ahmed, Saman, Aiylchiev, Stalbek, Alam, Manzur, Putri, Fauziah Asnely, Bastard, Mathieu, Docteur, Wisny, Gottlieb, Gary, Hewison, Catherine, Islam, Shirajul, Khachatryan, Naira, Kotrikadze, Tinatin, Khan, Uzma, Kumsa, Andargachew, Lecca, Leonid, Tassew, Yoseph Melaku, Melikyan, Nara, and Naing, Ye Yint

Subjects
ANTITUBERCULAR agents, IMIDAZOLES, MICROBIAL sensitivity tests, SPUTUM, TIME
Abstract

Delamanid should be effective against highly resistant strains of Mycobacterium tuberculosis , but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multidrug regimen, 80% of participants experienced sputum culture conversion within 6 months. Clinical Trials Registration. NCT02754765. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

9. Table of Contents.

Subjects
COMMUNICABLE diseases, MULTIDRUG-resistant tuberculosis, HEPATITIS B virus, PERIODICALS, PATIENTS, THERAPEUTICS
Abstract

The table of contents for the July 1, 2014 issue of the journal "Clinical Infectious Diseases" is presented.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results